Clinical Scorecard: Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

At a Glance

Key Highlights

• IKAR-001 co-expresses PEDF for neuroprotection and soluble CD46 for complement modulation.
• Current single pathway therapies for GA show modest effects and inconsistent improvements in visual function.
• Neuroprotection is critical for achieving meaningful functional outcomes in GA treatment.
• Next-generation gene therapies can target multiple pathways simultaneously.
• Clinical data shows significant slower decline in visual acuity with neuroprotective gene therapy.

Guideline-Based Recommendations

Diagnosis

• Assess visual function and anatomical changes in patients with GA.

Management

• Consider dual-pathway gene therapies for comprehensive treatment of GA.

Monitoring & Follow-up

• Regularly evaluate visual acuity and foveal sensitivity in treated patients.

Risks

• Potential for modest effects with current single pathway therapies.

Patient & Prescribing Data

Individuals diagnosed with geographic atrophy and other retinal diseases.

IKAR-001 aims to provide both anatomical and functional benefits through a dual-pathway approach.

Clinical Best Practices

• Utilize gene therapies that address multiple pathways for enhanced treatment outcomes.
• Incorporate neuroprotective strategies in the management of retinal diseases.

References

• Murakami et al. Long-term outcomes of neuroprotective gene therapy for retinitis pigmentosa.